Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Weighted Average and Diluted) (2022 - 2025)

Historic EPS (Weighted Average and Diluted) for Silence Therapeutics (SLN) over the last 4 years, with Q3 2025 value amounting to -$0.15.

  • Silence Therapeutics' EPS (Weighted Average and Diluted) rose 4000.0% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.45, marking a year-over-year increase of 176.8%. This contributed to the annual value of -$0.33 for FY2024, which is 1601.65% up from last year.
  • Per Silence Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.15 for Q3 2025, which was up 4000.0% from -$0.19 recorded in Q2 2025.
  • Silence Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.09 for Q4 2024, and its period low was -$0.25 during Q3 2024.
  • Its 4-year average for EPS (Weighted Average and Diluted) is -$0.13, with a median of -$0.16 in 2022.
  • In the last 5 years, Silence Therapeutics' EPS (Weighted Average and Diluted) soared by 15311.43% in 2024 and then crashed by 90000.0% in 2025.
  • Silence Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.16 in 2022, then dropped by 7.13% to -$0.17 in 2023, then soared by 153.11% to $0.09 in 2024, then tumbled by 269.18% to -$0.15 in 2025.
  • Its last three reported values are -$0.15 in Q3 2025, -$0.19 for Q2 2025, and -$0.2 during Q1 2025.